Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orion Diagnostica Oy

www.oriondiagnostica.com

Latest From Orion Diagnostica Oy

Market Intel: Expanding Elderly Population Gives Leg Up To Osteoporosis Dx Growth

The global market for osteoporosis diagnostic products is expected to expand from $253m in 2015 to $304m by 2020, fueled by a rising aging population and the need to test for osteoporosis and associated fracture risk. This article offers an in-depth look at the growth markets for both bone densitometer testing and biochemical marker tests, as well as the evolving competitive landscape, and the drivers and barriers to market entry.

Orthopedics Market Intelligence

Orion: Overcoming Inexperience

Finland's mid-80s decision to expand patenting inspired Orion Pharma to begin its own research. The firm quickly showed itself to be innovative and productive: coming up with several drugs interesting to Big Pharma licensees. But Orion has had difficulty turning its scientific achievement into commercial success. Partnering has not always gone well, while lack of management structures and limited funding have also hindered progress. Recent setbacks with Simdax, a drug for heart failure, spotlight the challenges of running effective clinical trials and gathering data for international regulators. Orion says it has learned its lessons, and instituted changes to help it overcome past problems. R&D and commercial operations are more closely managed; priorities are set and respected. The firm believes it can still make a success of Simdax, and has even higher hopes for the anti-anxiety drug that's next in its pipeline. A new partnership with Pharmacia brings it cash and expert assistance. Orion seems increasingly aware of, and able to meet, the challenges of being a Scandinavian company in a competitive international industry.
Strategy Business Strategies
See All

Company Information

  • Industry
  • In Vitro Diagnostics
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Cardiovascular
  • Gastrointestinal
  • Gynecological, Urological
  • Infectious & Viral Diseases
  • Inflammation
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Finland
  • Parent & Subsidiaries
  • Orion Diagnostica Oy
  • Senior Management
  • Matti Vaheri, Pres.
  • Contact Info
  • Orion Diagnostica Oy
    Phone: (358) 10 4261
    Koivu-Mankkaan tie 6 B
    P.O. Box 83 Espoo, FI-02200
    Finland
Advertisement
Advertisement
UsernamePublicRestriction

Register